Yu Zheng1, Eric Rovner2. 1. Department of Urology, Medical University of South Carolina, 96 Jonathan Lucas St., CSB 644, Charleston, SC, 29425, USA. 2. Department of Urology, Medical University of South Carolina, 96 Jonathan Lucas St., CSB 644, Charleston, SC, 29425, USA. rovnere@musc.edu.
Abstract
PURPOSE OF REVIEW: Urethral bulking agents are an effective treatment for stress urinary incontinence in select females. The material and techniques used for urethral bulking are constantly evolving. With the introduction of several new agents, there is an ongoing debate over which agent is the most effective, durable, and safe. RECENT FINDINGS: Current available bulking agents include Bulkamid®, Macroplastiue®, Durasphere®, Coaptite®, or Urolastic®. Each of these agents has its own biophysical properties that affect its efficacy and safety. Evidence evaluating bulking agents has increased over time but there is no definitive data that suggest superiority of one agent over another. The ideal urethral bulking agent for female stress incontinence has yet been identified. Currently available agents have acceptable short-term and medium-term efficacy with few adverse events.
PURPOSE OF REVIEW: Urethral bulking agents are an effective treatment for stress urinary incontinence in select females. The material and techniques used for urethral bulking are constantly evolving. With the introduction of several new agents, there is an ongoing debate over which agent is the most effective, durable, and safe. RECENT FINDINGS: Current available bulking agents include Bulkamid®, Macroplastiue®, Durasphere®, Coaptite®, or Urolastic®. Each of these agents has its own biophysical properties that affect its efficacy and safety. Evidence evaluating bulking agents has increased over time but there is no definitive data that suggest superiority of one agent over another. The ideal urethral bulking agent for female stress incontinence has yet been identified. Currently available agents have acceptable short-term and medium-term efficacy with few adverse events.
Authors: Alex Gomelsky; Stavros Athanasiou; Myung-Soo Choo; Michel Cosson; Roger R Dmochowski; Cristiano M Gomes; Ash Monga; Charles W Nager; Roy Ng; Eric S Rovner; Peter Sand; Hikaru Tomoe Journal: Neurourol Urodyn Date: 2018-12-04 Impact factor: 2.696
Authors: Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip Van Kerrebroeck; Arne Victor; Alan Wein Journal: Urology Date: 2003-01 Impact factor: 2.649
Authors: Joachim W Thüroff; Paul Abrams; Karl-Erik Andersson; Walter Artibani; Christopher R Chapple; Marcus J Drake; Christian Hampel; Andreas Neisius; Annette Schröder; Andrea Tubaro Journal: Eur Urol Date: 2010-11-24 Impact factor: 20.096
Authors: Michelle E Koski; Ekene A Enemchukwu; Priya Padmanabhan; Melissa R Kaufman; Harriette M Scarpero; Roger R Dmochowski Journal: Urology Date: 2011-01-08 Impact factor: 2.649
Authors: J Christian Winters; Roger R Dmochowski; Howard B Goldman; C D Anthony Herndon; Kathleen C Kobashi; Stephen R Kraus; Gary E Lemack; Victor W Nitti; Eric S Rovner; Alan J Wein Journal: J Urol Date: 2012-10-24 Impact factor: 7.450